A late-stage drug development company specific in oncology and endocrinology.

We have now anticipate reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year.’.. Aeterna Zentaris’ AEZS-108 receives orphan medicinal product designation for ovarian malignancy in Europe Aeterna Zentaris Inc. , a late-stage drug development company specific in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal item designation from the Committee for Orphan Medicinal Items of the European Medications Agency, for its substance AEZS-108 for the treating ovarian cancer. AEZS-108, the business’s doxorubicin targeted conjugate substance, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancers in Europe.All AHA programs are completed online, at the professionals own pace, fitting in properly with the busy life-style of today’s healthcare employees. Courses supplied by the AHA strive to prepare healthcare providers to effectively react to life-threatening cardiac occasions. A number of options are available, including programs in the areas of advanced cardiovascular existence support , basic existence support , pediatrics and stroke. Through eSimulation technology, students apply the knowledge learned to patient instances and see the total outcomes of their decision in real-time.

AIUM Ultrasound First Discussion board reveals part of ultrasound in health care solution The American Institute of Ultrasound in Medication hosted an Ultrasound Initial Forum in November 2012, which addressed the expanding role of ultrasound imaging as a first imaging examination and was specialized in encouraging the usage of ultrasound as a safe, effective, and affordable alternative to other diagnostic imaging modalities where scientific evidence supports its appropriateness.